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A B S T R A C T
Background
Epidemiological investigations of infectious disease are mainly dependent on indirect
contact information and only occasionally assisted by characterization of pathogen sequence
variation from clinical isolates. Direct sequence analysis of the pathogen, particularly at a
population level, is generally thought to be too cumbersome, technically difficult, and
expensive. We present here a novel application of mass spectrometry (MS)–based technology
in characterizing viral sequence variations that overcomes these problems, and we apply it
retrospectively to the severe acute respiratory syndrome (SARS) outbreak in Singapore.
Methods and Findings
The success rate of the MS-based analysis for detecting SARS coronavirus (SARS-CoV)
sequence variations was determined to be 95% with 75 copies of viral RNA per reaction, which
is sufficient to directly analyze both clinical and cultured samples. Analysis of 13 SARS-CoV
isolates from the different stages of the Singapore outbreak identified nine sequence variations
that could define the molecular relationship between them and pointed to a new, previously
unidentified, primary route of introduction of SARS-CoV into the Singapore population. Our
direct determination of viral sequence variation from a clinical sample also clarified an
unresolved epidemiological link regarding the acquisition of SARS in a German patient. We
were also able to detect heterogeneous viral sequences in primary lung tissues, suggesting a
possible coevolution of quasispecies of virus within a single host.
Conclusion
This study has further demonstrated the importance of improving clinical and epidemio-
logical studies of pathogen transmission through the use of genetic analysis and has revealed
the MS-based analysis to be a sensitive and accurate method for characterizing SARS-CoV
genetic variations in clinical samples. We suggest that this approach should be used routinely
during outbreaks of a wide variety of agents, in order to allow the most effective control.
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Introduction
During infectious disease outbreaks, due to either new or
established agents, extensive information gathering is re-
quired to enable identiﬁcation of the source, transmission
routes, and the effect of containment policies. It is becoming
increasingly clear that traditional approaches based on travel
and contact tracing are not sufﬁcient for tracking an
outbreak. New sequence-based techniques for pathogen
detection and identiﬁcation have the potential to become
perhaps the most important component of these investiga-
tions, as demonstrated in the recent worldwide effort in
ﬁghting the epidemic of severe acute respiratory syndrome
(SARS). The discovery of the SARS coronavirus (SARS-CoV)
as the etiological agent for SARS was a major breakthrough
[1], which was quickly followed by the successful sequencing
of the whole genome of the virus [2,3]. Genome sequence
comparison between this new coronavirus and the three
known classes of coronavirus revealed a similar genome
structure, but minimum homology at the amino acid level,
strongly suggesting that the SARS-CoV was a new class of
coronavirus [2,3,4]. A comparative sequence analysis of 14
SARS isolates from different countries suggested a moderate
genetic diversity among the SARS isolates and thus implied a
slow evolution of the SARS-CoV genome [5]. Furthermore,
sequence variation analyses of SARS-CoV isolates demon-
strated that common genetic variations in the SARS-CoV
genome could be used as ‘‘molecular ﬁngerprints’’ to
partition the viral isolates into different genetic lineages,
track the transmission of a speciﬁc viral lineage, and infer the
origin of infection [5,6]. Therefore, the characterization of
SARS-CoV’s genetic variations is not only instrumental for
understanding its genetic diversity and genome evolution but
also important for tracking its transmission and under-
standing its epidemiological pattern in human populations.
Direct sequence analysis of a pathogen in a large number of
clinical samples, particularly at a population level, is generally
cumbersome, technically challenging, and expensive. There-
fore, a rapid, sensitive, high-throughput, and cost-effective
screening method would greatly facilitate large-scale charac-
terization of genetic variation of pathogens at a population
level. A mass spectrometry (MS)–based method for detecting
single nucleotide polymorphisms has been routinely used as a
high-throughput method for genotyping human samples,
and, thus, we sought to extend this methodology to detect
pathogen sequence variations. Here, we demonstrate the high
sensitivity of the MS-based analysis in detecting SARS-CoV
sequence variations and apply it to analyzing both cultured
viral isolates and uncultured tissue samples of SARS-CoV.
Methods
Patients and Samples
The SARS-CoV samples used in the sensitivity study were
previously described [7]. Brieﬂy, ﬁve in vitro samples were
generated by spiking 200-ll human whole-blood samples with
SARS-CoV virus obtained from a Vero E6 cell culture of an
anonymous Singapore patient.
Vero cell cultured viral isolates were obtained from 13
Singapore patients: the presumed index case (patient
Sin2500) of the Singapore SARS outbreak, whose date of
illness onset was 25 February 2004; three primary contacts
(patients Sin2677, Sin2774, and Sin2748), whose dates of
onset were 9 March 2004 (Sin2677 and Sin2774) and 14 March
2004 (Sin2748); one secondary contact (patient Sin2679), who
was believed to have contracted SARS from index patient
Sin2500 through another primary contact not included in
this study and whose date of illness onset was 15 March 2004;
and another eight patients (Sin842, Sin845, Sin846, Sin847,
Sin848, Sin849, Sin850, and Sin852), who were believed to be
the ﬁfth- or six-generation contacts of index patient Sin2500
(based on contact tracing records) and whose dates of illness
onset ranged from 2 April to 14 April 2004. All the patients
ﬁtted the World Health Organization case deﬁnition for
probable SARS [8]. The virus was cultured in vero cells
following isolation from respiratory samples (three endotra-
cheal tube swabs, three throat swabs, one nasal swab, two
nasopharyngeal aspirates, and four lung tissues) obtained
from the patients between 0 and 11 d after onset of
symptoms. Uncultured lung tissue samples were also obtained
from patients Sin842, Sin848, Sin849, and Sin852. Bronchoal-
veolar lavage material was obtained from a serologically
conﬁrmed German patient with SARS who had been traveling
on the same ﬂight as an early Singaporean patient with SARS
who was later hospitalized in Germany [9]. Virus could not be
isolated from the sample owing to its inappropriate storage.
RNA Extraction and cDNA Synthesis
For the spiked human blood samples, RNA was extracted
from 200 ll of blood into 50 ll of water using a HighPure
RNA kit (Roche, Basel, Switzerland). For the clinical samples,
RNA was extracted into 30 ll of water using a QiAmp viral
RNA mini kit (Qiagen, Valencia, California, United States).
RNA samples were reverse transcribed into cDNA using 2 ll
of RNA as template, a SuperScript kit (Invitrogen, Carlsbad,
California, United States), and 13 sequence-speciﬁc primers
[10]. All cDNA products were puriﬁed by ethanol precip-
itation and then resuspended in 20 ll of water.
Real-Time Quantitative PCR Analysis
Real-time quantitative PCR analyses of the RNA samples
from spiked human blood were performed using a Light-
cycler Sars-CoV quantiﬁcation kit (Roche). Each analysis was
done using 1 ll of RNA and in accordance with the
manufacturers’ instructions.
Single Nucleotide Variations of SARS-CoV
Twenty-one single nucleotide variations (SNVs) of SARS-
CoV were analyzed in this study. Eight of these were identiﬁed
from our previous sequence analysis of ﬁve Singapore SARS-
CoV viral isolates and represent variations [5], and 13 SNVs
were identiﬁed from a more recent genome sequence analysis
of additional Singapore SARS-CoV viral isolates. The former
eight SNVs were used in evaluating the sensitivity of MS-based
genotyping analysis in detecting SARS-CoV viral genotypes,
and the later 13 SNVs, as well as ﬁve of the former eight SNVs,
were used to genotype the patient-derived samples.
SNV Analysis
A primer extension genotyping assay was designed for each
SARS-CoV SNV using SpectroDesigner software (Sequenom,
San Diego, California, United States) and analyzed using the
MassARRAY system (Sequenom) and the recommended pro-
tocol for the MADLI-TOF (matrix-assisted laser desorption
ionization/time-of-ﬂight) MS-based genotyping analysis [11].
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One microliter of cDNA (equivalent to 0.1 ll of RNA from 1 ll
of spiked human blood) was used as template in each analysis.
Statistical Analysis of Sensitivity
The analytical detection limit of the combined RNA
preparation/RT-PCR/MALDI-TOF MS system was determined
by probit analysis [12] using the Statgraphics Plus 5.0 software
package (Statistical Graphics, Jena, Germany).
Results
Sensitivity for Detecting SARS-CoV SNVs
Prior to determining viral sequence variants in clinical
samples, we measured the sensitivity of the MS-based assay
for detecting SARS-CoV sequence variations by analyzing
eight SNVs in in vitro human blood samples spiked with
SARS-CoV. The viral RNA copy numbers in ﬁve spiked
human blood samples were quantiﬁed by real-time PCR
analysis and determined to be 1.64 3 106 (SB1), 3.84 3 103
(SB2), 2.173 103 (SB3), 6.213 102 (SB4), and 1.203 102 (SB5)
copies per microliter (Figure S1). The three samples (SB3,
SB4, and SB5) with the lowest virus copy numbers were used
to determine the sensitivity of the MS-based assay.
We were able to successfully type the virus in 16 of the 16
analyses of the SB3 sample (equivalent to 217 RNA copies per
reaction), 12 of the 15 analyses of the SB4 sample (equivalent to
62 RNA copies per reaction), and six of the 15 analyses of the
SB5 sample (equivalent to 12 RNA copies per reaction).
According to probit analysis, this corresponds to a 95%
probability of detection when at least 75 copies of viral RNA
(95% conﬁdence interval, 59–107 copies) are present per
reaction, and still a 50% detection chance at 38 copies of virus
RNA per reaction (95% conﬁdence interval, 29–53 copies). All
64 sham spiked samples gave negative genotype calls.
Sequence Variant Determination of SARS-CoV in Viral Isolates
Having demonstrated the high sensitivity of the MS-based
analysis, we typed 18 SARS-CoV SNVs in the cultured viral
isolates from nine Singapore patients, including ﬁve early
Singapore cases (Sin2500, Sin2774, Sin2748, Sin2677, and
Sin2679) and four later Singapore cases (Sin842, Sin848,
Sin849, and Sin852).
Of the 18 SNVs analyzed, nine were detected in at least two
SARS isolates (Table 1). Assuming that a common sequence
variation originated through a single mutation in a host and
was then propagated by subsequent infection to others, the
sharing of a speciﬁc sequence variant by different viral
isolates suggests that either these viral isolates share a
common ancestor or they have direct ancestor–descendant
relationship. Sequence variants at the nine common SNV
sites were used to reconstruct the molecular relationship
among the nine viral isolates. The pattern of the shared
variants among the nine viral isolates (Table 1) clearly
indicated two major molecular lineages of isolate (Figure 1).
One lineage includes the four early isolates from patients
Sin2500, Sin2774, Sin2748, and Sin2677, and the other
includes the early isolate from patient Sin2679 and the four
later isolates. The ﬁrst lineage is deﬁned by the sequence
variant T:C:T at SNV positions19,084, 23,174, and 28,268,
whereas the second lineage is deﬁned by the sequence variant
C:T:C. Both the variants are distinct from the presumed
ancestral sequence variant C:C:C observed in the Urbani viral
isolate. The later Singapore isolates were also differentiated
from the early isolates by the sequence variant pattern at SNV
positions 22,549 and 23,735.
In addition, the sequence variant sharing pattern at SNVs
28,008, 548, 1,727, and 13,347 can further differentiate the
four ﬁfth- and six-generation isolates into three different
sub-lineages (Figure 1) deﬁned by three distinct variants:
C:T:T:C in the isolate from patient Sin842, T:T:T:C in the
isolate from patient Sin849, and T:C:C:T in the isolates from
patients Sin852 and Sin848 (Table 1). To further conﬁrm this
three-sub-lineage pattern observed in the later Singapore
isolates, we typed another four later Singapore isolates, from
Table 1. Genotypes of Five Early and Four Later Singapore SARS-CoV Isolates in 18 SNVs
SNV Category SNV Positiona Urbani Isolate Early Isolates Later Isolates
Sin2500 Sin2774 Sin2748 Sin2677 Sin2679 Sin842 Sin849 Sin852 Sin848
Isolated/shared 19,084 C T T T T C C C C C
23,174 C C C C C T T T T T
28,268 C T T T T C C C C C
22,549 C C C C C C T T T T
23,735 A A A A A A G G G G
28,008 C C C C C C C T T T
548 T T T T T T T T C C
1,727 T T T T T T T T C C
13,347 C C C C C C C C T T
Isolate-specific 3,421 C C C C C C T C C C
14,807 C C C C C C C C C T
19,241 T NA NA NA NA NA T T C T
23,279 T NA NA NA NA NA T T C T
23,792 C C T C C C C C C C
26,205 C C C C C C C C C T
26,428 G A G G G G G G G G
26,509 T NA NA NA NA NA T T T C
27,111 A A A A G A A A A A
a SNV positions are numbered according to their nucleotide positions in the genome sequence of the Urbani isolate.
NA, not analyzed.
DOI: 10.1371/journal.pmed.0020043.t001
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patients Sin845, Sin846, Sin847, and Sin850, at ﬁve critical
SNVs (19,084, 28,008, 548, 1,727, and 13,347). The detected
sequence variations in the four new isolates supported the
three-sub-lineage pattern in the later Singapore isolates
(Table 2; Figure 1). The second and third sub-lineages are
more closely related to each other than to the ﬁrst one, as all
the members of the latter two sub-lineages show the variant T
at SNV position 28,008, whereas the two members of the ﬁrst
sub-lineage show the variant C.
The molecular relationship among the viral isolates derived
from MS-based viral sequence analysis is consistent with the
one derived from the whole-genome sequence analysis of the
same isolates [13], clearly demonstrating that a small subset of
commonly shared variances can be used as ‘‘molecular
signature’’ to differentiate and thus track viral isolates.
Direct Sequence Variation Determination of SARS-CoV in
Primary Lung Tissue Samples
We also typed the 18 SNVs in four uncultured lung tissue
samples from patients Sin842, Sin848, Sin849, and Sin852,
and compared their sequence variations with their matched
cultured isolates (Table 3).
Of the 72 direct sequence variation comparisons (18 SNVs
in four sample pairs), nine differences were identiﬁed. Six of
these were due to heterogeneous sequences in primary tissue
samples. For example, the cultured isolate from patient
Sin849 showed the sequence variant T:T:C at SNV positions
548, 1,727, and 13,347, a subset of the heterogeneous T/C:T/
C:T/C variant observed in the matched lung tissue sample
from the same patient. Direct comparison of the MS
spectrums of the three different sequence variants (T, T/C,
and C) at SNV position 1,727 in Figure 2 clearly ruled out the
possibility of variant miscall. More interestingly, the hetero-
geneous variant T/C:T/C:T/C in the primary lung tissue sample
revealed both of the two existing variants of T:T:C and C:C:T
seen in other cultured and lung tissue samples (Table 3).
In addition, another three sequence variant differences
were observed between the paired cultured and tissue
samples from patient Sin848 at SNV positions14,807,
26,205, and 26,509, where the tissue sample showed the
sequence variant C:C:T, but the matched culture isolate
showed the variant T:T:C (Table 3). In all three SNV positions,
the cultured isolate showed novel sequence variants, whereas
the primary lung tissue showed the Urbani isolate’s variants
(see Table 3).
Confirmation of the Singapore Origin of a German SARS-
CoV Isolate
The application of tagging and thus tracking of SARS-CoV
strains using viral lineage- and/or strain-speciﬁc sequence
variants was further demonstrated in our investigation of a
clinical sample from a German patient. This patient stayed in
Hanoi, Vietnam, before sharing an airplane ﬂight with an early
Singapore SARS patient on his way to New York via Frankfurt
[9]. German health authorities assumed that this patient was
infected somewhere in Hanoi, Vietnam, although the possi-
bility of him being infected by a Singapore SARS-CoV strain
during his ﬂight to New York could not be ruled out.
We genotyped the virus directly from a brochoalveolar
lavage specimen from the German patient at four SNV
positions (19,084, 23,792, 26,428, and 27,111) that were
distinctive for the early Singapore SARS-CoV isolates (see
Table 1). The sequence of the isolate from the German
patient was determined to be T:C:G:A at these SNV positions.
The detection of the variant T at SNV position 19,084 in the
isolate from the German patient strongly suggested that this
patient was indeed infected by an early Singapore SARS-CoV
strain, as the T sequence variant at position 19,084 was
detected only in the early Singapore isolates [5,6] and is
clearly different from the C variant at position 19,084
observed in the Vietnam-originated isolates [6,14]. Further-
more, this German isolate’s sequence variant, T:C:G:A, was
detected only in the isolate from the Singapore primary case
Sin2748, suggesting that this German patient was probably
infected by a SARS-CoV strain originating from or closely
related to the SARS-CoV strain of the Singapore primary case
Sin2748 and not from the Hanoi outbreak. Indeed, the
T:C:G:A variant is also present in the Frankfurt-1 isolate [15],
which was contracted from the early Singaporean patient
traveling on the same ﬂight as the German patient.
Figure 1. The Molecular Relationship among 13 Singapore SARS-CoV
Isolates Based on the Genotype Sharing Pattern of the Viral Isolates
DOI: 10.1371/journal.pmed.0020043.g001
Table 2. Genotypes of Two Early and Eight Later Singapore SARS-CoV Isolates at Five SNV Positions
SNV Position Ubani Early Isolates Later Isolates
Sin2500 Sin2679 Sin842 Sine846 Sin849 Sin850 Sin852 Sin848 Sin845 Sin847
19,084 C T C C C C C C C C C
28,008 C C C C C T T T T T T
548 T T T T T T T C C C C
1,727 T T T T T T T C C C C
13,347 C C C C C C C T T T T
DOI: 10.1371/journal.pmed.0020043.t002
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Discussion
Through the application of this MS mini-sequencing
approach to the SARS outbreak in Singapore we have
demonstrated the precision that pathogen sequence data
can add to an epidemiological investigation. We analyzed 18
SARS-CoV SNVs and determined the molecular relationship
among the viral isolates from 13 Singapore SARS patients (see
Figure 1) from different stages of the Singapore outbreak. The
molecular relationship among the patients’ viral isolates
derived from our MS-based viral sequence analysis is not
consistent with the current understanding of the clinical
transmission relations between these patients. According to
contact tracing records, patient Sin2500 was believed to have
been the index case of the Singapore SARS outbreak and to
have introduced the SARS-CoV virus into the Singapore
population following a visit to the Hotel M (Hong Kong) [5,6].
Patients Sin2774, 2748, and Sin2677 were believed to have
been infected directly by the index case Sin2500, and patient
Sin2679 was believed to have been infected by the index case
through another, unidentiﬁed, primary patient [5]. Given the
pattern of sequence variations observed in the viral isolates, in
order for this presumed clinical transmission relationship
among these ﬁve patients to be correct, one has to assume that
during viral transmission from index case Sin2500 to
secondary case Sin2679 via an unidentiﬁed primary case
(two human-to-human transmissions), two reverse mutations
at SNV positions 19,084 and 28,268 and one novel mutation at
SNV position 23,174 occurred. Although this is not impos-
sible, it is unlikely considering the observed mutation rate
among the post–Hotel M SARS-CoV isolates [5,16,17]. A more
parsimonious explanation would be a single-mutation scenar-
io in which, instead of contracting the virus from the
presumed index case Sin2500, the secondary patient Sin2679
and all the later Singapore cases were infected by a virus strain
from the Hotel M cluster through another, as yet unidentiﬁed,
route, and during this transmission, a novel mutation
occurred at SNV position 23,174. Thus, patient Sin2679 or
another unidentiﬁed Singapore patient from whom patient
Table 3. Comparison of Paired Direct Tissue Samples and Vero Cell Cultured Isolates of SARS-CoV
SNV Category SNV Position Urbani Sin842 Sin849 Sin852 Sin848
Vero Vero Tissue Vero Tissue Vero Tissue Vero Tissue
Isolated/shared 19,084 C C C C C C C C C
23,174 C T T T T T T T T
28,268 C C C C C C C C C
23,735 A G G G G G G G G
28,008 C C C T T T T T T
548 T T T T T/C C C C C
1,727 T T T T T/C C C C C
13,347 C C C C T/C T T T T
Isolate-specific 3,421 C T T C C C C C C
14,807 C C C C C C C T C
19,241 T T T T T C T/C T T/C
23,279 T T T T T C T/C T T
23,792 C C C C C C C C C
26,205 C C C C C C C T C
26,428 G G G G G G G G G
26,509 T T T T T T T C T
27,111 A A A A A A A A A
DOI: 10.1371/journal.pmed.0020043.t003
Figure 2. MS Spectrums of the Three Distinct Genotypes at SNV Position
1,727
The T example is from the cultured viral isolate from patient Sin849,
the T/C example is from the uncultured lung tissue sample from
patient Sin849, and the C example is from the cultured viral isolate
from patient Sin852.
DOI: 10.1371/journal.pmed.0020043.g002
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Sin2679 contracted SARS should be the index case of all the
late-generation Singapore SARS patients. Further viral
genetic characterization of additional Singapore SARS cases,
especially early-generation ones, may shed light on this
hypothesis. Unidentiﬁed secondary SARS-CoV infection
routes from Guangdong to Hong Kong were also suggested
by the genetic characterization of SARS-CoV isolates,
although none of these contributed substantially to the
subsequent Hong Kong outbreak [6,18].
A further application of MS-based viral sequence variation
analysis in tracking the virus strain and thus the transmission
of SARS-CoV was demonstrated by our conﬁrmation of the
Singapore origin of a SARS-CoV isolate from a German
patient. Travel and contact tracing records for this German
patient indicated more than one potential exposure to SARS-
CoV, and because virus could not be cultured from the
patient, it was difﬁcult to pinpoint the origin of his infection
by classical sequencing methods that require virus enrich-
ment by culture. By genotyping the four SNV positions that
showed unique variants in the early Singapore SARS-CoV
isolates, we conﬁrmed that this German patient was indeed
infected by an early Singapore virus strain, most likely in a
hitherto unnoticed aircraft transmission event from an early
Singaporean patient who was later hospitalized with SARS in
Germany [9]. Therefore, our results clearly demonstrate the
usefulness of the sequence variation information as molec-
ular ﬁngerprint in ‘‘tagging’’ SARS-CoV viral strains.
Direct viral sequence variation analysis of uncultured lung
tissue samples identiﬁed cases of heterogeneous viral sequen-
ces in single patient samples. As the SARS-CoV virus is a
single-strand RNA virus, the discovery of different sequences
in a single tissue sample suggests the presence of multiple
viral sequence variants, or quasispsecies, within the host when
the sample was retrieved. Our result has further conﬁrmed a
recent observation of SARS-CoV quasispecies in individual
patients [19] and is consistent with observations in other viral
infections. Furthermore, direct comparison between cultured
and uncultured samples from the same patient conﬁrmed the
existence of the heterogeneous viral sequences only in the
uncultured tissue sample, which suggests that of the two
initial variants in the human host, only one survived in the
vero cell culture. This raises a concern that viral genetic
characterization in cultured viral isolates may not capture the
whole sequence variation spectrum of a virus in a patient
population.
Our study has clearly demonstrated the advantages of MS-
based genetic analysis as a method for large-scale viral genetic
characterization in clinical samples. Firstly, MS-based analysis
has high sensitivity, providing successful detection of virus
more than 95% of the time at virus concentrations as low as
75 RNA copies per reaction (equivalent to a detection
sensitivity of 103–104 RNA copies per milliliter), which is
close to the detection limit of real-time RT-PCR based
diagnostic tests (demonstrated to be 5–85 copies of viral RNA
per reaction) [7,20,21,22] and within the concentration range
reported for SARS-CoV in respiratory and plasma samples
[9,20,22,23,24]. Typical RT-PCR sequencing usually requires
as many as 1,000 copies of template, as large PCR fragments
are typically ampliﬁed with less efﬁciency than the small
fragments (about 100 bp) that are commonly used in MS-
based analysis. Secondly, our detection of heterogeneous viral
sequences in single clinical samples demonstrated the
accuracy of the MS-based assay in characterizing SARS-CoV
sequence variations. Thirdly, MS-based assay requires only a
small amount of starting material for genetic character-
ization, 0.1 ll of RNA per reaction in the present study.
Currently, MS-based genotyping analysis of human genetic
variation is routinely done in a multiplex fashion, where
multiple single nucleotide polymorphisms are genotyped
simultaneously in a single assay. It is thus conceivable that the
development of a multiplexing MS-based SNV assay for
SARS-CoV could further reduce the required amount of
starting material, which would be especially beneﬁcial for
analyzing uncultured clinical samples, in which viral materials
are often limited. Multiplexing analysis of MS-based assays
also greatly reduces the cost of analysis to about US$0.10–
$0.20 per analysis (depending on the level of multiplexing),
which is much cheaper than conventional sequence analysis,
whose cost is typically a few dollars per analysis. Therefore,
MS-based sequence variation analysis is a sensitive, accurate,
cost-effective, and high-throughput method for conﬁrming
putative variations and characterizing known variations in
clinical samples, especially for large-scale population studies.
MS-based sequence variation analysis is complementary to
the identiﬁcation of new sequence variation by direct
sequence analysis and is particularly suitable for investigating
agents for which there is already extensive sequence
information. Direct sequence analysis is still the ‘‘gold
standard’’ for identifying new sequence variations, but it is
inefﬁcient and is not necessary for characterizing known
sequence variations in a large number of samples. A
combination of initial characterization of genome sequence
by direct sequence analysis in a subset of samples and the
subsequent analysis of informative genetic variations via a
MS-based approach is more efﬁcient and suitable for large-
scale population investigations. The genome sequences of a
wide variety of pathogens and strains are being rapidly
accumulated. In bacterial pathogens, strain sequence infor-
mation is frequently limited to a relatively small number of
genes (where using all of them simultaneously might be
appropriate), whereas in viruses such as inﬂuenza, extensive
genomic knowledge is accumulating. Such accumulation of
both partial- and whole-genome sequence information for
pathogens will further extend the usefulness of this approach.
In summary, our reassessment of the SARS-CoV trans-
mission route in Singapore using MS-based viral sequence
variation analysis highlighted the limitation of conventional
epidemiological analysis based on travel and contact tracing,
and the importance of informing clinical and epidemiolog-
ical investigation of pathogen transmission by genetic
analysis. With its demonstrated high throughput [25],
sensitivity, accuracy, and cost effectiveness in determining
viral sequence variations, MS-based genetic analysis can
greatly facilitate the large-scale epidemiological investiga-
tions of SARS-CoV and other agents of infectious disease, and
may allow for real-time investigation in outbreak situations.
Supporting Information
Figure S1. Detection of SARS-CoV by Real-Time Quantitative PCR in
Spiked Human Blood Samples
The x-axis denotes the cycle number of the quantitative PCR assay,
and the y-axis denotes ﬂuorescence intensity (F2) over the back-
ground level. RNA standards were as follows: 1.05 3 106 copies per
reaction (line a), 1.01 3 105 copies per reaction (line b), 9.4 3 103
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copies per reaction (line c), 8.93 102 copies per reaction (line d), and
1.073 102 copies per reaction (line e). The virus loads determined in
the ﬁve spiked human blood samples were as follows: SB1, 1.643 106
copies per reaction; SB2, 3.843 103 copies per reaction; SB3, 2.173
103 copies per reaction; SB4, 6.213 102 copies per reaction; and SB5,
1.203 102 copies per reaction. NTC, non-template control.
Found at DOI: 10.1371/journal.pmed.0020043.sg001 (244 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html) ac-
cession number for the Frankfurt-1 isolate is AY291315 and for the
Urbani isolate is AY278741.
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Patient Summary
Background Molecular biology (studying the makeup and function of
molecules) is increasingly being used to track outbreaks of infectious
diseases. For example, molecular biology can help to identify the cause
of a disease (such as a virus, bacterium, or parasite) and understand how
it spreads.
Why Was This Study Done? These researchers had previously used
molecular biology techniques to study different strains of the SARS virus,
which causes the often fatal disease called severe acute respiratory
syndrome. They had found that different strains could be distinguished
from each other on the basis of specific genetic ‘‘fingerprints.’’ They now
wanted to find quick and easy ways to determine the identity of
particular viral strains found in sick patients.
What Did the Researchers Do? They used a molecular biology
technique called mass spectrometry. They took samples from patients
(such as blood samples and nasal swabs) and determined whether they
could detect the SARS virus, identify specific strains, and distinguish
between them.
What Did They Find? They found that mass spectrometry is a useful
tool for detecting the SARS virus and for distinguishing between
different strains. They also found that they could use this tool to help
understand how the SARS virus had been transmitted between specific
patients.
What Are the Limitations? For this technique to work, the researchers
needed pre-existing information about genetic differences between
strains. This means that detailed DNA sequencing is necessary to find
these differences in the first place and to discover new ones as the virus
evolves.
What Next? The authors suggest that combining initial genetic
sequencing of the different strains with the mass spectrometry
technique to analyze subsequently large numbers of samples is the
most efficient and cost-effective approach.
More Information Online
Public access Web pages on SARS from Science Magazine: http://
www.sciencemag.org/feature/data/sars/
News article on the SARS genome on the Genome Network News Web
site: http://www.genomenewsnetwork.org/articles/05_03/sars_3.shtml
Genome Institute of Singapore (GIS): http://www.gis.a-star.edu.sg/
homepage/default.jsp
GIS’s press release on differences between SARS strains: http://
www.gis.a-star.edu.sg/homepage/gismediapress.jsp?pid=19
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